

## DAFTAR PUSTAKA

- Abdin, A.A., Baalash, A.A., Hamooda, H.E., 2010. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. *J. Diabetes Complications* 24, 168–178. <https://doi.org/10.1016/j.jdiacomp.2009.01.005>
- Awtry, E.H., Loscalzo, J., 2000. Aspirin. *Circulation* 101, 1206–1218.
- Bastard, J.-P., Jardel, C., Bruckert, E., Blondy, P., Capeau, J., Laville, M., Vidal, H., Hainque, B., 2000. Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss. *J. Clin. Endocrinol. Metab.* 85, 5.
- Baynest, H.W., 2015. Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. *J. Diabetes Metab.* 6.
- Bertoluci, M.C., Rocha, V.Z., 2017. Cardiovascular Risk Assessment In Patients With Diabetes. *Diabetol. Metab. Syndr.* 9, 25. <https://doi.org/10.1186/s13098-017-0225-1>
- Caldeira, D., Alves, M., David, C., Costac, J., Ferreira, J.J., Pinto, F.J., 2019. Aspirin in The Primary Prevention of Cardiovascular Disease on Diabetic Patients: Systematic Review and Meta-Analysis. *Prim. Care Diabetes* 8.
- Campbell, 2000. Epidemiology and Clinical Presentation of Type 2 Diabetes. *Value Health* 3.
- Canto, E.D., Ceriello, A., Ryde'n, L., Ferrini, M., Hansen, T.B., Schnell, O., Standl, E., Beulens, J.W., 2019. Diabetes As A Cardiovascular Risk Factor: An Overview of Global Trends of Macro and Micro Vascular Complications. *Eur. J. Prev. Cardiol.* 26, 25–32.
- Cartika, H., 2017. *Kimia Farmasi II*. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Davi, G., Catalano, I., Averna, M., Notarbartolo, A., Strano, A., Ciabattini, G., Patrono, C., 1990. Thromboxane Biosynthesis and Platelet Function In Type 2 Diabetes Mellitus. *N. Engl. J. Med.* 322.
- Decroli, E., 2019. *Diabetes Melitus Tipe 2*. Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas, Padang.
- Departemen Kesehatan Republik Indonesia, 2014. *Farmakope Indonesia*, 5th ed. Departemen Kesehatan Republik Indonesia, Jakarta.
- Departemen Kesehatan Republik Indonesia, 2008. *Pedoman Pengendalian Diabetes Melitus dan Penyakit Metabolik*. Direktorat Pengendalian Penyakit Tidak Menular, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Departemen Kesehatan Republik Indonesia, Jakarta.
- Dressman, J.B., Nair, A., Abrahamsson, B., Barends, D.M., Groot, D.W., Kopp, S., Langguth, P., Polli, J.E., Shah, V.P., Zimmer, M., 2012. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Acetylsalicylic Acid. *J. Pharm. Sci.* 101, 2653–2667.
- Eikelboom, J.W., Hirsh, J., Spencer, F.A., Baglin, T.P., Weitz, J.I., 2012. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American

College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  
*CHEST* 141, e89S-e119S.

- Einarson, T.R., Acs, A., Ludwig, C., Panton, U.H., 2018. Prevalence Of Cardiovascular Disease In Type 2 Diabetes: A systematic Literature Review Of Scientific Evidence From Across The World In 2007–2017. *Cardiovasc. Diabetol.* 17, 83. <https://doi.org/10.1186/s12933-018-0728-6>
- Ekström, N., Cederholm, J., Zethelius, B., Eliasson, B., Fhärm, E., Rolandsson, O., Miftaraj, M., Svensson, A.-M., Gudbjörnsdottir, S., 2013. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. *BMJ Open* 3, 9.
- Evangelista, V., Berardis, G.D., Totani, L., Avanzini, F., Levantesi, G., Marelli, G., Pupillo, M., 2007. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. *J. Thromb. Haemost.* 5, 8.
- Gaglia, M.A., Clavijo, L., 2013. Cardiovascular Pharmacology Core Reviews: Aspirin. *J. Cardiovasc. Pharmacol. Ther.* 18, 505–513.
- Gonçalves, L.H., Dusse, L.M.S., Fernandes, A.P., Gomes, K.B., Sôter, M.O., Alves, M.T., Rodrigues, K.F., Freitas, F.R., Pianett, G.A., Carvalho, M. das G., 2011. Urinary 11-dehydro thromboxane B2 levels in type 2 diabetic patients before and during aspirin intake. *Clin. Chim. Acta* 412, 5.
- Hackett, E., Jacques, N., 2009. Type 2 Diabetes Pathophysiology and Clinical Feature. *Clin. Pharm.* 1.
- Hovens, M.M.C., Snoep, J.D., Groeneveld, Y., Frlich, M., Tamsma, J.T., Huisman, M.V., 2008. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. *Diabetes Obes. Metab.* 10, 668–674. <https://doi.org/10.1111/j.1463-1326.2007.00794.x>
- Hudspeth, B., 2018. The Burden of Cardiovascular Disease in Patients With Diabetes. *Am. J. Manag. Care* 24, S268–S272.
- International Diabetes Federation, 2019. *IDF Diabetes Atlas*, 9th ed. International Diabetes Federation.
- Kong, J.S.W., Teuber, S.S., Gershwin, M.E., 2007. Aspirin and Nonsteroidal Anti-Inflammatory Drug Hypersensitivity. *Clin. Rev. Allergy Immunol.* 23.
- Laakso, M., 2010. Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms. *Diabetes Care* 33.
- Lee, S., Kim, I.T., Park, H.B., Hyun, Y.K., Kim, Y.J., Song, S.O., Kim, H., 2011. High-sensitivity C-reactive Protein Can Predict Major Adverse Cardiovascular Events in Korean Patients with Type 2 Diabetes. *J Korean Med Sci* 26, 6.
- Leung, W.Y., So, W., Stewart, D., Lui, A., Tong, P.C., Ko, G.T., Kong, A.P., Ma, R.C., Chan, F.K., Yang, X., Chiang, S., Chan, J.C., 2009. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients - a longitudinal observational study. *Cardiovasc. Diabetol.* 8, 57. <https://doi.org/10.1186/1475-2840-8-57>

- Lin, K.J., Caterina, R.D., Rodríguez, L.A.G., 2014. Low-Dose Aspirin and Upper Gastrointestinal Bleeding in Primary Versus Secondary Cardiovascular Prevention. *Circ Cardiovasc Qual Outcomes* 7, 8.
- McDonagh, P.F., Hokama, J.Y., Gale, S.C., Logan, J.J., Davis-Gorman, G., Goldman, S., Copeland, J.G., 2003. Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients Chronic platelet activation in diabetic heart patients. *J. Diabetes Complications* 17, 11.
- McQuaid, K.R., Laine, L., 2006. Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials. *Am. J. Med.* 119, 624–638.
- Ogawa, H., Nakayama, M., Morimoto, T., Uemura, S., Kanauchi, M., Doi, N., Jinnouchi, H., Sugiyama, S., Saito, Y., 2008. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial. *JAMA* 300, 8.
- Okada, S., Morimoto, T., Ogawa, H., Sakuma, M., Soejima, H., Nakayama, M., Sugiyama, S., Jinnouchi, H., Waki, M., Doi, N., Horii, M., Kawata, H., Somekawa, S., Soeda, T., Uemura, S., Saito, Y., investigators for the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, 2013. Effect of Low-Dose Aspirin on Primary Prevention of Cardiovascular Events in Japanese Diabetic Patients at High Risk. *Circ. J.* 77, 3023–3028. <https://doi.org/10.1253/circj.CJ-13-0307>
- Ong, G., Davis, T.M.E., Davis, W.A., 2010. Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting. *Diabetes Care* 33, 317–321.
- Patrono, C., 2019. *Antiplatelet Therapy*, in: Platelets. Elsevier Inc, Italy.
- Perkumpulan Endokrinologi Indonesia, 2019. *Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus Dewasa Tipe 2 di Indonesia*. PB PERKENI, Jakarta.
- Poudel, R.R., 2013. Renal Glucose Handling in Diabetes and Sodium Glucose Cotransporter 2 Inhibition. *Indian J. Endocrinol. Metab.* 17.
- Ritu, N., Asheesh, S., Dinesh, B., 2012. Aspirin: An Overview of Randomized Controlled Trials. *Int. J. Res. Pharm. Sci.* 2, 53–67.
- Rungby, J., Schou, M., Warrer, P., Ytte, L., Andersen, G.S., 2017. Prevalence of Cardiovascular Disease and Evaluation of Standard of Care in Type 2 Diabetes: A Nationwide Study in Primary Care. *Cardiovasc. Endocrinol.* 6, 145–151.
- Sacco, M., Pellegrini, F., Roncaglioni, M.C., Avanzini, F., Tognoni, G., Nicolucci, A., 2003. Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial. *Diabetes Care* 26, 3264–3272. <https://doi.org/10.2337/diacare.26.12.3264>
- Saito, Y., Okada, S., Ogawa, H., Soejima, H., Sakuma, M., Nakayama, M., Doi, N., Jinnouchi, H., Waki, M., Masuda, I., Morimoto, T., 2017. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized

- Controlled Trial. *Circulation* 135, 659–670.  
<https://doi.org/10.1161/CIRCULATIONAHA.116.025760>
- Santilli, F., Davì, G., Consoli, A., Cipollone, F., Mezzetti, A., Falco, A., Taraborelli, T., Devangelio, E., Ciabattini, G., Basili, S., Patrono, C., 2006. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. *J. Am. Coll. Cardiol.* 47, 391–397.  
<https://doi.org/10.1016/j.jacc.2005.03.079>
- Sasso, F.C., Marfella, R., Pagano, A., Porta, G., Signoriello, G., Lascar, N., Minutolo, R., Carbonara, O., Persico, M., Piscione, F., De Nicola, L., Torella, R., Paolisso, G., 2015. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. *Acta Diabetol.* 52, 239–247.  
<https://doi.org/10.1007/s00592-014-0623-x>
- Schrör, K., 2016. *Acetylsalicylic Acid*, Second. ed. Wiley-VCH Verlag GmbH & Co. KGaA., Weinheim.
- Schulze, M.B., Rimm, E.B., Li, T., 2004. C-Reactive Protein and Incident Cardiovascular Event Among Men With Diabetes. *Diabetes Care* 27, 889–894.
- Sease, J., Shealy, K., 2016. *Diabetes Mellitus*, in: Pharmacotherapy Principles & Practice. McGraw-Hill Education, New York, p. 653.
- Seidu, S., Kunutsor, S.K., Sesso, H.D., Gaziano, J.M., Buring, J.E., Roncaglioni, M.C., Khunti, K., 2019. Aspirin Has Potential Benefits for Primary Prevention of Cardiovascular Outcomes In Diabetes: Updated Literature-Based And Individual Participant Data Meta-Analyses Of Randomized Controlled Trials. *Cardiovasc. Diabetol.* 18, 70.  
<https://doi.org/10.1186/s12933-019-0875-4>
- Shah, A.D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C.P., Deanfield, J., Smeeth, L., Timmis, A., Hemingway, H., 2015. Type 2 Diabetes and Incidence of Cardiovascular Diseases: A Cohort Study in 1,9 Million People. *Lancet Diabetes Endocrinol* 3, 105–113.
- Sinha, S., 2020. *Aspirin Uses, Dosage, Side Effects & Interactions*. Drugs.com. URL <https://www.drugs.com/aspirin.html> (accessed 6.8.21).
- The ASCEND Study Collaborative Group, 2018. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. *N. Engl. J. Med.* 379, 1529–1539. <https://doi.org/10.1056/NEJMoa1804988>
- Triplitt, C.L., Repas, T., Alvarez, C., 2017. *Diabetes Mellitus*, in: Pharmacotherapy: A Pathophysiologic Approach. McGraw-Hill Education, New York, p. 2709.
- Vane, J.R., Botting, R.M., 2003. The Mechanism of Action of Aspirin. *Thromb. Res.* 110, 255–258.
- Vinik, A.I., Erbas, T., Park, T.S., Nolan, R., Pittenger, G.L., 2001. Platelet Dysfunction in Type 2 Diabetes. *Diabetes Care* 24, 10.
- World Health Organization, 2019. *Classification of Diabetes Mellitus*. World Health Organization, Geneva, Switzerland.

World Health Organization, 2016. *Global Report On Diabetes*. World Health Organization, Geneva, Switzerland.

Yki-Järvinen, H., 2011. *Diabetes Mellitus*, in: Oxford Textbook of Endocrinology and Diabetes. Oxford University Press, New York.